-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Benzinga·08/12/2026 17:20:44
Listen to the news
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.